Heloisa Nascimento

Heloisa Nascimento

Auto-generated profile, based on publicly available information

Heloisa Nascimento

Department of Ophthalmology, Universidade Federal de São Paulo, Sao Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in The Lancet
Verified
Journal Article
Closed access
PMPaula M Marinho
Paula M Marinho
AMAllexya A A Marcos
Allexya A A Marcos
ARAndré C Romano
André C Romano
HNHeloisa Nascimento
Heloisa Nascimento
RBRubens Belfort
Rubens Belfort

1 May 2018 in Ophthalmology
Verified
Journal Article
Open access
ADAndrew D. Dick
Andrew D. Dick
JRJames T. Rosenbaum
James T. Rosenbaum
HAHassan A. Al-Dhibi
Hassan A. Al-Dhibi
RBRubens Belfort
Rubens Belfort
ABAntoine P. Brézin
Antoine P. Brézin
OZOlga Ziouzina
Olga Ziouzina
An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.

10 December 2019 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
RARupesh Agrawal
Rupesh Agrawal
AAAniruddha Agarwal
Aniruddha Agarwal
DJDouglas A. Jabs
Douglas A. Jabs
AKAera Kee
Aera Kee
ITIlaria Testi
Ilaria Testi
FGfor the Collaborative Ocular Tuberculosis Study (COTS) Group
for the Collaborative Ocular Tuberculosis Study (COTS) Group
Purpose: To standardize a nomenclature system for defining clinical phenotypes, and outcome measures for reporting clinical and research data in patients with ocular tuberculosis (OTB). Methods: Uveitis experts initially administered and further deliberated the survey in an open meeting to determine and propose the preferred nomenclature for terms related to the OTB, terms describing the clinical phenotypes and treatment and reporting outcomes. Results: The group of experts reached a consensus on terming uveitis attributable to tuberculosis (TB) as tubercular uveitis. The working group introduced a SUN-compatible nomenclature that also defines disease “remission” and “cure”, both of which are relevant for reporting treatment outcomes. Conclusion: A consensus nomenclature system has been adopted by a large group of international uveitis experts for OTB. The working group recommends the use of standardized nomenclature to prevent ambiguity in communication and to achieve the goal of spreading awareness of this blinding uveitis entity.

30 August 2021 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
JSJanaína Jamile Ferreira Saraceno
Janaína Jamile Ferreira Saraceno
GSGuilherme Macedo Souza
Guilherme Macedo Souza
LFLuciana Peixoto dos Santos Finamor
Luciana Peixoto dos Santos Finamor
HNHeloisa Moraes Nascimento
Heloisa Moraes Nascimento
RBRubens Belfort
Rubens Belfort
The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development. However, important questions regarding SARS-CoV-2 vaccines remain. A case of complete Vogt-Koyanagi-Harada (VKH) Syndrome that occurred 4 days following SARS-CoV-2 vaccination and another patient that developed VKH 14 days post COVID-19 clinical onset are presented. A causal relationship between COVID-19 and uveitis may exist.

17 August 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
HLHenrique M. Leber
Henrique M. Leber
LSLeticia Sant’aNa
Leticia Sant’aNa
NSNina R. Konichi da Silva
Nina R. Konichi da Silva
MRMariana C. Raio
Mariana C. Raio
TMThiago Jose Muniz Machado Mazzeo
Thiago Jose Muniz Machado Mazzeo
CSCarlos E. de Souza
Carlos E. de Souza
Purpose: To describe a case of acute thyroiditis and bilateral optic neuritis associated with SARS-CoV-2 vaccination. Methods: A single case report from a tertiary referral center. Results: The patient described in the following case report developed acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination. The patient underwent pulse therapy followed by oral tapering corticosteroid therapy with an improvement of the bilateral disc swelling and the visual field, and recovery of thyroid-stimulating hormone to the normal limits. Conclusions: Although the association between immunization and the onset of demyelinating manifestations of the central nervous system is well documented, this is the first reported case of bilateral optic neuritis and acute thyroiditis and subsequent to administration of vaccination against SARS-CoV-2.

21 January 2020 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
CSCarlos E. Souza
Carlos E. Souza
LLLuiz H. Lima
Luiz H. Lima
HNHeloísa Nascimento
Heloísa Nascimento
CZClaudio Zett
Claudio Zett
RBRubens Belfort
Rubens Belfort
Background: To objectively evaluate YAG laser vitreolysis for symptomatic vitreous floaters using color photo imaging. Methods: In this interventional and prospective study, 32 eyes of 32 patients with symptomatic vitreous floaters secondary to posterior vitreous detachment (PVD) were treated with a single session of yttrium aluminum garnet (YAG) laser. Primary outcomes were objective and subjective changes measured by masked grading of color fundus photographs and National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25), respectively. Secondary outcomes included Early Treatment Diabetic Retinopathy Study (ETDRS), best-corrected visual acuity (BCVA) and adverse events. Wilcoxon signed-rank test was used to analyze the results of the objective and subjective assessments at each time point. P < 0.05 was considered statistically significant. Results: Thirty-two patients (32 eyes; 13 men and 19 women) with symptomatic vitreous floaters were enrolled in this study (mean age: 59.4 years). All study patients were followed up for 6 months. Following the laser vitreolysis, there was a statistically significant improvement in both the near visual function (z = − 2.97; p = 0.003; r = 0.633) and visual disturbance rate (z = − 3.97; p < 0.001; r = 0.84). Distance visual function did not show statistically significant difference after the laser procedure (p = 1.00). Color fundus photograph did reveal vitreous opacity improvement over time in 93.7% of study eyes (partial improvement in 37.5% and total improvement in 56.2% of study eyes). During the follow-up period, recurrence of vitreous floaters, BCVA deterioration and adverse events were not observed. Conclusions: YAG laser vitreolysis decreased the amount of vitreous floaters opacities seen on color fundus imaging and improved related symptoms according to the NEI VFQ-25 responses.